Introduction
Inflammatory bowel disease (IBD) is an intestinal inflammatory disease characterized by chronic nature and tendency to relapse. Crohn's disease (CD) has a long and persistent disease duration, is recurrent, and can seriously affect the quality of life of patients. Therefore, CD has been designated by the World Health Organization as an intractable digestive disease. In Europe, there are approximately 2.5-3 million IBD patients, costing approximately €4.6-5.6 billion in health-care spending each year. 1 The general clinical symptoms of Chinese patients are relatively mild: There are fewer incidences of symptoms outside of the intestine as well as fewer complications, and fistula and perianal complications are rare. 2 However, with the recent improvement of China's Gross Domestic Product (GDP) and quality of life, the incidence of CD clearly trended upward, the age of onset has tended to be younger, 2 and familial aggregation has become less significant. 3 Although it is currently considered that the pathogenesis and development of CD is closely related to interactions between the internal and external environments of the body, susceptibility genes, and immunomodulatory factors, the precise pathogenic mechanism remains unclear. 4, 5 In the past 20 years, international collaboration via genomewide association studies investigated potential IBD pathogenic genes. In these studies, CD occurrence was closely related to autophagy and immunity. 6 miRNAs are small noncoding RNAs (21-23 nucleotides in length) that bind to specific target mRNAs, thereby post-transcriptionally inhibiting gene expression. 7, 8 Although the biological functions of only a small portion of the miRNAs have been elucidated, their importance is exemplified by roles in the regulation of gene expression, the cell cycle, and development as well as in immune response regulation. 7, 9 miRNA binding sites are often located in the 3 0 untranslated region (UTR) of a target mRNA transcript, leading to mRNA degradation or translational inhibition. An increasing number of studies have focused on miRNA function in the intestinal immune system: These results provide evidence that miRNAs can regulate intestinal epithelial tight junction permeability 10 and T helper cell (Th)-17-mediated inflammation and autophagy. 11, 12 Secondgeneration sequencing methods have been applied to active CD patient samples versus healthy control groups to measure differential miRNA expression profiles in the peripheral blood and inflammatory and noninflammatory areas of intestinal tissues. 13, 14 However, few studies have focused on miRNA expression in the mucosae of affected areas (the terminal ileum, sigmoid colon, and rectum) in active CD patients; [15] [16] [17] the ascending colon and the terminal ileum are the most common sites of CD, 18 protein biomarkers of ascending colon biopsies may differentiate Crohn's disease from ulcerative colitis (UC) throughout proteomic analysis, 19 and no reports have investigated miRNA mechanisms from the perspective of the ascending colon mucosa of CD patients. Hence, the miRNA expression profile characteristics of the ascending colon mucosa remain unclear.
The goal of this study was to observe whether miRNA expression profiles were altered in the ascending colon mucosa of active CD patients and if these profiles differed between mucosa originating from inflammatory and noninflammatory regions. We further sought to identify differentially expressed mRNAs in inflammatory ascending colon mucosae from CD patients.
Methods
Subjects and ascending colon tissue collection. Adult patients were from the CD specialty department at the Shanghai Institute of Acupuncture and Meridian and Zhongshan Hospital of Fudan University from July 2009 to May 2010. All patients were type L2B1 (colonic, non-stricturing, and nonpenetrating) and were enrolled according to the Montreal classification criteria. 20 Patients were evaluated using the Crohn's Disease Activity Index (CDAI), and all enrolled patients had CDAI scores greater than 150 points. A portion of biopsy specimens were from ascending colon regions with inflammation (CD, ulcer surface, and three biopsies/area), and the others were from normal regions (CD, 8 cm above the inflammatory mucosa, and three biopsies/area). Healthy volunteers who were screened and provided colon biopsies were designated as the healthy control (HC) group. HC and CD biopsy specimens were collected into pre-labeled cryopreservation vials, immediately soaked in liquid nitrogen and stored at À80°C until testing. All patients and healthy volunteers were from a randomized controlled clinical trial (Clinical Trial Registration: ChiCTR-TRC-10000950), which was approved by the Ethics Committee of the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine in affiliation with the Shanghai University of Traditional Chinese Medicine (no: 2009-02); all subjects provided informed consent. The methods were carried out in accordance with the approved guidelines RNA extraction and quality control. TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from the biopsy samples. The miRNeasy mini kit (QIAGEN, Hilden, Germany) was also used for miRNA separation and purification. A NanoDrop (ND-1000; NanoDrop Technologies, Wilmington, DE, USA) was used for quality determination and quantification of total RNA, and RNA integrity was observed following 1% agarose gel electrophoresis. The Agilent 2100 (Agilent Technologies, Palo Alto, CA, USA) was used for quality control. Total RNA samples with an RNA integrity number greater than 7 were used for microarray analysis.
MicroRNA microarray analysis. Shanghai KangChen Bio-tech measured the miRNA expression profiles of the ascending colon mucosa samples using the miRCURY ™ LNA Array (v.16.0, Exiqon, Vedbaek, Denmark). The miRNA hybridization method was based on the procedures provided with the miRCURY LNA. RNA samples were labeled with Hy3 fluorescence using the miRCURY array labeling kit (Exiqon, Vedbaek, Denmark). Fluorescence-labeled miRNAs were identified after hybridization by sequencing. The hybridized miRNAs were washed using the buffer kit (Exiqon, Vedbaek, Denmark), dried, and scanned using a GenePix 4000B array scanner (Molecular Devices, Sunnyvale, CA, USA). Luciferase reporter assays. Mutated 3 0 UTR gene sequences were inserted into the XbaI and FseI sites of the pGL3 vector (Genechem, Shanghai, China). HEK293T cells transfected with miRNA mimics (RiboBio, Guangzhou, China) or a negative control were seeded into 24-well plates. The pGL3 vector (0.1 μg) with the inserted 3 0 UTR sequence was cotransfected with the pRL-TK vector (0.02 μg) using X-treme GENE HP (Roche Diagnostics, Indianapolis, IN, USA). After 24 h, the cells were harvested according to the manufacturer's protocol (Promega Corporation, Fitchburg, WI, USA) and firefly and Renilla luciferase activities were detected using the Dual-Luciferase Reporter Assay System (Promega Corporation) with a Tecan Infinite reader. Taget genes and sequence of hsa-miR-16-1 and hsa-miR-142-3p were shown in Table S6 .
Data analysis. MicroRNAs with significant differences in expression were normalized using the double-filtering criteria: adjusted P-value (FDR) < 0.05 and absolute log2 fold change (absolute log2FC) > 1. Pathway and Gene Ontology (GO) analyses, cluster analysis (Cluster 3.0) and TreeView analysis (Stanford University, Stanford, CA, USA) were applied to the results. miRNA and mRNA expression differences were detected and tested using Kruskal-Wallis and Holm-Bonferroni post-hoc tests. 21 Measurement data are expressed as the means ± standard deviation, and comparisons between two groups were conducted using independent sample t-tests (SPSS17.0, Chicago, IL, USA).
Figures were plotted using Graphpad Prism 5 (San Diego, CA, USA). P-values of < 0.05 were indicative of statistically significant differences.
Results
A comprehensive summary of sample information is listed in Table S1 . CD samples were divided into ascending colon mucosal samples with inflammation (iCD) or without inflammation (niCD). The total number of samples included seven iCD, seven niCD, and seven healthy controls. Overall, intestinal mucosa samples (from 14 individuals: seven CD patients and seven healthy volunteers) were obtained (Fig. 1a) . Specific sample information, including ethnic background, CDAI, previous treatments, and other clinical data, is listed in Table S2 . Morphological observation of the patient intestinal mucosal tissues is shown in Figure S1A -S1C. Figure S1A shows that in the HC group, the epithelium was intact, with no ulcerations. The intestinal glands were arranged in an orderly manner in the lamina propria. Figure S1B shows that in the iCD group, the mucosal epithelium was damaged, with ulcerations and obvious hemorrhage. The intestinal glands were , hsa-miR-1973; , hsa-miR-1205; , hsa-miR-5481; , hsa-miR-491-3p.
reduced in size. In addition, there was substantial lymphocytic cell infiltration in the intestinal mucosa and submucosa. Figure S1C shows that in the niCD group, there was a small amount of hyperemia and inflammatory cell infiltration in the intestinal mucosa and submucosa. The intestinal glands were arranged in an orderly manner.
Overlaps in miRNAs differentially expressed between inflammatory and noninflammatory CD mucosae. The iCD and HC groups had eight differentially expressed miRNAs in common with the niCD and HC groups and 45 overlaps with the iCD and niCD groups; the niCD and HC groups had five differentially expressed miRNAs in common with the iCD and niCD groups, and the three groups had only one common overlap, hsa-miR-223 (Fig. 1b) . We compared the expression of the four most significantly upregulated miRNAs (with defined names) (miR-144, miR-451, miR-31, and miR-142-3p) and the four most significantly downregulated miRNAs (miR-1973, miR-1205, miR-5481, and miR-491-3p) in iCD samples compared with HC samples. In inflammatory colonic mucosae of CD patients, miR-144, miR-451, miR-31, and miR-142-3p demonstrated significantly higher expression levels than in healthy colonic mucosae or noninflamed areas, where the expression levels of these four miRNAs were similar (Fig. 1c) . In contrast, the expression levels of miR-1973, miR-1205, miR-5481, and miR-491-3p were significantly reduced in the inflammatory colonic mucosae of CD patients relative to healthy colonic mucosae. The expression of miR-1205 was reduced in both inflammatory and noninflammatory areas; however, the expression levels of miR-1973, miR-5481, and miR-491-3p in noninflammatory areas were similar to those of healthy tissues (Fig. 1d) .
MicroRNA expression profiles change in inflammatory ascending colon mucosa. We found that the miRNA expression profile in the ascending colon mucosae differed significantly between the iCD and HC groups. Of the 1257 miRNA detected, 78 miRNAs differed significantly between the iCD and HC groups (P < 0.05, FDR < 0.05), with 43 miRNAs upregulated and 35 downregulated (Figs 1b,2b) . The heat map of differentially expressed miRNAs suggests that the CD group of samples differed from the HC group (Fig. 2a) .
MicroRNA expression profile changes in noninflammatory ascending colon mucosae. Our microarray analysis demonstrated that, compared with the HC group, two miRNAs were upregulated and 18 miRNAs were downregulated in the noninflammatory ascending colon mucosae of CD patients (Figs 1b,3b) . Cluster analyses of the differentially expressed miRNAs suggest differences between samples from the niCD group and those from the HC group (Fig. 3a) .
MicroRNA expression levels differ between inflammatory and noninflammatory regions of the ascending colon. We compared the changes in mucosal miRNA expression profiles between the inflammatory and noninflammatory regions of the ascending colon. Expression and cluster analyses of miRNAs with significant differences revealed differences between the two sample groups. Among the miRNAs differentially expressed in the inflammatory versus noninflammatory areas, 73 were upregulated and 27 were downregulated (Figs 1b,4a,b) .
MRNA expression profiles of the inflammatory ascending colon in CD patients differ from healthy controls. Among the 36 333 probes (NimbleGen HG 18.0), 3370 genes demonstrated significant differences between the HC and iCD groups (Log2FC absolute values > 1 and adjusted P-value < 0.05), of which 2169 were upregulated and 1201 were downregulated in the iCD group compared with the HC group. The pathways associated with the differentially upregulated and downregulated genes and genes involved in each pathway are listed in Tables S3 and S4 ; more signaling pathways were associated with the upregulated genes than the downregulated genes. Pathways of upregulated genes closely related to CD pathology mainly included antigen processing and presentation, pathogenic Escherichia coli infection, cytokine-cytokine receptor interaction, and intestinal immune network for IgA production. Pathways of downregulated genes closely related to CD pathology mainly included the Hedgehog signaling pathway, pathways in cancer, natural killer cell-mediated cytotoxicity, and the mTOR signaling pathway.
We observed that inflammatory factors and cytokines related to immune functions were dysregulated in the inflammatory ascending colon of CD patients. Among them, IL1RL2, IL17, IL13, and IL22RA2 showed varying degrees of downregulation in inflammatory tissues, while IL-7R, IL1RB, IL6R, IL32, CXCL14, IL18BP, and CXCL5 showed varying degrees of upregulation (Fig. 5d ).
MRNA and miRNA expression is correlated in the HC and iCD groups. We selected genes with high levels of expression in the inflammatory areas of CD patients and differentially expressed miRNAs to conduct correlation analyses of gene and miRNA expression (Log2 expression). We found that REG4, PLA2G2A, HLA-DQB1, and CXCL5 were highly expressed in the inflammatory areas of CD patients compared with HC (Log2FC values = 6.76, 5.81, 3.87, and 2.58, respectively), and these genes highly correlated (r 2 > 0.97) with different miRNAs. For example, there were positive correlations between REG4 and miR-21 (r 2 = 0.9991, Fig. S3A ) and between PLA2G2A and miR-126 (r 2 = 0.9996, Fig. S3C ). Conversely, there were negative correlations between CXCL5 and let-7i (r 2 = 0.9943, Fig. S3B ) and between HLA-DQB1 and miR-106b* (r 2 = 0.9706, Fig. S3D ).
Quantitative real-time polymerase chain reaction validation. We chose three miRNAs (let-7a, let-7i, and miR-21) that were upregulated in the iCD group (another seven patients) compared with healthy controls (another seven individuals) as well as three downregulated miRNAs (miR-491-3p, miR-106b*, and let-7d*) to be validated via qRT-PCR. The microarray results are shown in Figure 2b . The expression levels of let-7a, let-7i, and miR-21 were significantly increased in inflammatory areas of CD patients by 4.25-fold, 2.5-fold, and 2.68-fold, respectively, (Fig. 5a) ; those of miR-491-3p, miR106b*, and let-7d* were significantly reduced in the inflammatory areas of CD patients by 0.33-fold, 0.53-fold, and 0.44-fold, respectively (Fig. 5c ). We also verified the expressions of LIMK1, TBKBP1, and TMEM30B in healthy control samples and those from inflammatory areas of CD patients. The results showed that, compared with the HC group, the expression levels of LIMK1 and TBKBP1 were reduced in the inflammatory areas of CD by 0.50-fold and 0.33-fold, respectively, while that of TMEM30B was upregulated in the inflammatory areas of CD by 4.02-fold; these differences were all significant (Fig. 5b ).
C10orf54 is a potential target gene of miR-16-1.
Compared with the negative control group, the luciferase assay results of wild-type C10orf54 and SON suggested that miR-16-1 reduced expression by 37% (P = 0.004) and 20% (P = 0.014), respectively, suggesting that miR-16-1 could bind to the 3 0 UTR-1 of these target genes and inhibit their expression. Compared with the corresponding wild-type control groups, the luciferase assay results of the C10orf54 and SON mutant 3 0 UTR constructs demonstrated that miR-16-1 led to an increase of 23% (P = 0.005) and a decrease of 3%, respectively. These data indicate that miR-16-1 cannot bind to the mutated C10orf54 3 0 UTR and thus cannot inhibit its expression (Fig. 6b) . We therefore concluded that miR-16-1 can directly target the 3 0 UTR-1 region of the C10orf54 target gene to suppress its expression. We further observed a negative correlation between miR-16 expression and the mRNA expression level of C10orf54 (r 2 = 0.7126, Fig. 6a ). We also investigated the effects of miR-142-3p on the luciferase activities of its predicted target genes ATG16L1 and VPS24. Compared with the negative control group, the luciferase activity results showed reductions in the expression levels of wild-type ATG16L1 and VPS24 of 10% (P = 0.029) and 17% (P = 0.031), respectively, suggesting that miR-142-3p can bind to the 3 0 UTR-1 of these target genes and inhibit their expression. Compared with the corresponding wild-type groups, luciferase activity test results of the mutants increased the expression levels of ATG16L1 and VPS24 by 11% and 10% in the presence of miR-142-3p; however, these differences were not significant, suggesting that miR-142-3p has weak binding capacities with ATG16L1 and VPS24, through which it can inhibit their expression (Fig. S2 ).
Discussion
To our knowledge, the present study is the first to investigate miRNA expression profiles in the ascending colon mucosae of patients with active CD from the perspective of inflammatory and noninflammatory tissues. Our results show that inflammatory and noninflammatory regions of ascending colon mucosae have unique miRNA expression profiles. miRNAs are involved in various biological processes, such as cell differentiation and proliferation, apoptosis, and autophagy, and are closely related to the inflammation-mediated condition of CD. 22, 23 Previous studies have reported the miRNA expression profiles of inflammatory and noninflammatory colonic mucosa, of colonic mucosa in active and inactive disease phases, and of peripheral blood. 13, 16 Although some immune-related miRNAs have similar expression profiles, most miRNAs have unique expression patterns. 24, 25 Previously, using healthy volunteers as controls, we compared the miRNA expression profiles in the mucosae of five sigmoid colon samples affected by CD and six ileum samples affected with CD. Microarray analysis determined that three miRNAs (miR-106a, miR-23b, and miR-191) were highly expressed and two miRNAs (miR-19b and miR-629) were downregulated in the sigmoid colon samples afflicted with CD, while four miRNAs (miR-16, miR-21, miR-223, and miR-594) were upregulated and no miRNAs were downregulated in the inflamed ileum. 16 In addition, it has been found that miR-495-5p is downregulated in the inflammatory terminal ileum of CD patients, while miR-361-3p was upregulated and let-7b-5p was downregulated in the noninflammatory terminal ileum. 15 Previous studies in pediatric IBD patients investigated miRNA expression profile changes in the rectum and serum and identified three miRNAs (miR-192, miR-142-3p, and miR-21) with significantly upregulated expression. 17 In a study that did not distinguish specific areas of the colon, CD patients with colonic inflammation expressed five upregulated miRNAs (miR-9, miR-126, miR-130a, miR-181C, and miR-375) compared with healthy volunteers, while four miRNAs (miR-9*, miR-30a*, miR-30c, and miR-223) were upregulated in noninflammatory colonic mucosae. 26 The miRNA expression profiles of peripheral blood from two adult CD patients showed significant upregulation of miR-199a-5p, miR-362-3p, and miR-532-3p. In another study, miR-16, miR23a, miR-29a, miR-106a, miR-107, miR-126, miR-191, and miR-200c were upregulated, while in another study, miR-340* and miRplus-E1271 were upregulated. 13, 27 The differentially expressed miRNAs identified from these studies are not exactly the same, which may be due to differing factors such as sample size, CD patient characteristics (age, drug history, with or without surgery, etc.), and subject population demographics (nationality and race). 15 Although the ascending colon is a site frequently affected by CD, until now, no studies have focused on the miRNA expression profiles of inflammatory and noninflammatory regions of ascending colon mucosae in CD patients.
In our study, we found that hsa-miR-16, hsa-miR-21, and hsa-miR-223 expression levels were increased in the inflammatory ascending colon mucosa, and the results are similar to the expression patterns in inflammatory ileal mucosa 16 while showing significant differences from inflammatory sigmoid colon mucosa. miR-21 is closely related to myocardial fibrosis, and miR-146b is associated with ischaemia and hypoxia. 28 In addition, miR-144, miR-451, miR-31, and miR-142-3p, which were also upregulated in inflammatory colonic mucosa, demonstrated significant differences in expression between the inflammatory ascending colon mucosa of active CD patients and healthy controls (Log2 FC > 2.6, Fig. 1c ). Among these, miR-31 has been closely related to inflammation-related colon cancer, is dynamically changed, 29 and can act on target genes such as SNAIL, TWIST2, and ZEB1. 30 It has been reported that expression of the miR-29 family is reduced in colonic mucosa associated with small intestinal narrowing; miR-29b inhibits TGF-β-induced intestinal fibrosis in CD patients 31, 32 and can directly regulate collagen genes (COL1, COL3, and COL4). 33 Interestingly, the expression levels of miR-32*, miR-106b*, and let-7d* were reduced in the inflammatory tissues compared with healthy controls and increased compared with the noninflammatory tissue of the CD ascending colon. Let-7 is involved in the regulation of immune inflammation by regulating the activity of NF-κB and mediating the downregulation of IL-6 in macrophages. 34 We analyzed the coexpression of miRNAs and mRNAs in the inflammatory ascending colon mucosae of CD patients and in the ascending colon mucosae of healthy volunteers. CXCL5, 14 and 16, and IL-13, 17, and 32 as well as other chemokines and cytokines closely related to inflammation were all upregulated at sites of colon inflammation (Fig. 5d ). Among these, CXCL5 and let-7i were negatively correlated (Fig. S3B) . CXCL14, CXCL5, and IL-17 are all highly expressed in inflammatory tissues and have demonstrated hypermethylation in UC but not CD patients. This feature might be used as a diagnostic marker for these two diseases. 35 During the inflammation phase of IBD, the number of Th17 cells is increased, while IL-13, IL-17, and CXCL5 are all upregulated, suggesting that IL-13, IL-17, and CXCL5 are closely related to the pathology of enteritis and act closely with the PI3K-AKT signaling pathway. 36, 37 IL-32 is a newly discovered pro-inflammatory cytokine that can activate the P38 and NF-κB signaling pathways to play a role in the immune response of IBD, but its specific roles with other proteins are still to be elucidated. 38 It has been reported that DUOX2 and DUOXA2 are upregulated and closely related to inflammation in active UC. In our study, compared with healthy volunteers, DUOX2 was upregulated in inflammatory ascending colon mucosae of CD patients, 39 whereas DUOXA2 did not show significant differences. DUOX2 is an NADPH oxidase homologue and can release hydrogen peroxide. Another NADPH oxidase homologue, NOX1, also showed increased expression in iCD. Mesalazine therapy in UC patients acts by inhibiting DUOX2-mediated production of hydrogen peroxide, thereby reducing ROS-induced intestinal mucosal damage. 39 In addition, we observed that, in comparison with healthy volunteers, the pro-inflammatory cytokines demonstrating significant changes in the inflammatory ascending colon, such as REG4, PLA2G2A, and HLA-DQB1, were also abnormally regulated and significantly upregulated in other inflammatory tissues. REG4 is a gene involved in anti-microbial reactions, and its expression in the inflammatory CD ascending colon was increased 108-fold compared with that of the healthy human; this upregulation was positively correlated with miR-21 (Fig. S3A ). This result is consistent with previous studies showing that REG4 expression in CD was only upregulated in comparison with healthy volunteers, and there was no change between CD and UC patients. 40 REG4 is an important member of the regeneration gene family. It participates in the proliferation and differentiation of intestinal cells and plays an important role in the diagnosis of intestinal tumours. PLA2G2A is an α-defensin specifically expressed in Paneth cells, and its expression level can reflect the number of Paneth cells. Our results show that PLA2G2A was highly expressed in the ascending colon mucosae of CD patients (56-fold) and was positively correlated with miR-126 (Fig. S3C) , consistent with previous studies. 41 The human leukocyte antigen (HLA) allelic polymorphism is closely related to the genetic susceptibility of Han people to CD. Our results suggest that HLA-DQB1 was upregulated in the inflammatory ascending colon, while other members of the HLA gene family showed varying degrees of increased expression (Supplementary Material), suggesting that patients have a greater risk of CD susceptibility; furthermore, the expression of these genes was negatively correlated with miR-106b* (Fig. S3D) . Based on the prediction of miRNA target genes, we calculated the relevance and selected miRNAs and target genes for luciferase reporter gene assays. We discovered that miR-16-1 mimics could directly act on the 3 0 UTR of the wild-type C10orf54, inhibiting its expression. However, the inhibitory effect of the miR-16-1 mimics disappeared following mutation of the C10orf54 3 0 UTR (Fig. 6b) , and the two were negatively correlated. Upregulation of miR-16 in the inflammatory areas of the ascending colon mucosa probably inhibits the expression of C10orf54, which in turn causes immune inflammatory responses in the ascending colon, and reduction in miR-16 expression suggests the possibility of canceration of the inflammatory colon. 42 miR-142-3p can act on the autophagyrelated CD-susceptibility gene ATG16L1 in the CD ascending colon and play a regulatory role in colonic epithelial autophagy. 43 We selected a number of miRNAs and validated these miRNAs via qRT-PCR. Compared with healthy volunteers, the expression levels of miR-21, let-7a, and let-7i were significantly upregulated in the inflammatory ascending colon mucosae of adult L2B1 CD patients, while those of miR-491-3p, miR-106b*, and let-7d* were significantly reduced. We also verified the expression of mRNAs and found that TMEM30B was significantly upregulated (fourfold), while LMK1 and TBKBP were significantly reduced.
In summary, our data suggest that dysregulation of miRNA expression is mainly restricted to the inflammatory ascending colon mucosa of adult L2B1 CD patients: There are no obvious changes in noninflammatory ascending colon mucosa, and the characteristics of the different miRNA expression profiles can be used to distinguish whether there is inflammatory infiltration in the colon.
The main limitation is that the differences in the miRNA expression profiles between inflammatory and noninflammatory ascending colon mucosae may be due to the different cell types collected via biopsy. In addition, the degree of inflammatory infiltration may affect miRNA expression in the inflammatory ascending colon mucosa. It will be important that the relationship between miRNAs and immune inflammation warrants further investigation.
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